Gilead Sciences, Inc. (NASDAQ:GILD) Holdings Increased by Kintegral Advisory LLC

Kintegral Advisory LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 63.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 132,162 shares of the biopharmaceutical company’s stock after buying an additional 51,403 shares during the quarter. Gilead Sciences comprises 0.9% of Kintegral Advisory LLC’s holdings, making the stock its 22nd biggest position. Kintegral Advisory LLC’s holdings in Gilead Sciences were worth $9,068,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. Conning Inc. grew its stake in shares of Gilead Sciences by 8.6% in the 2nd quarter. Conning Inc. now owns 559,933 shares of the biopharmaceutical company’s stock worth $38,356,000 after purchasing an additional 44,192 shares during the last quarter. Simmons Bank grew its stake in shares of Gilead Sciences by 1.1% in the 2nd quarter. Simmons Bank now owns 43,030 shares of the biopharmaceutical company’s stock worth $2,952,000 after purchasing an additional 464 shares during the last quarter. Financial Connections Group Inc. acquired a new position in shares of Gilead Sciences in the 2nd quarter worth approximately $34,000. Harbour Investments Inc. increased its position in shares of Gilead Sciences by 29.0% in the second quarter. Harbour Investments Inc. now owns 9,055 shares of the biopharmaceutical company’s stock worth $621,000 after acquiring an additional 2,037 shares in the last quarter. Finally, AustralianSuper Pty Ltd increased its position in shares of Gilead Sciences by 150.0% in the second quarter. AustralianSuper Pty Ltd now owns 1,016,686 shares of the biopharmaceutical company’s stock worth $69,755,000 after acquiring an additional 610,012 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on GILD shares. Maxim Group dropped their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday, May 1st. Robert W. Baird reissued a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a research report on Thursday, June 20th. Cantor Fitzgerald reissued a “neutral” rating and issued a $70.00 target price on shares of Gilead Sciences in a research report on Friday, August 9th. BMO Capital Markets lifted their target price on shares of Gilead Sciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Thursday, August 15th. Twelve equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $81.94.

Gilead Sciences Stock Up 2.0 %

NASDAQ GILD traded up $1.56 during trading on Wednesday, reaching $78.56. The company’s stock had a trading volume of 6,210,157 shares, compared to its average volume of 7,190,603. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. The stock has a market capitalization of $97.87 billion, a PE ratio of 218.22, a PEG ratio of 3.37 and a beta of 0.18. The business has a 50-day moving average price of $72.40 and a 200-day moving average price of $70.20. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $87.86.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.92%. The ex-dividend date is Friday, September 13th. Gilead Sciences’s payout ratio is 855.56%.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now directly owns 96,380 shares in the company, valued at $6,614,559.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, insider Johanna Mercier sold 5,490 shares of the company’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the transaction, the insider now directly owns 114,979 shares in the company, valued at approximately $8,506,146.42. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $68.63, for a total transaction of $137,260.00. Following the transaction, the insider now owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.